Relationship between dietary inflammatory index and metabolic dysfunction associated steatotic liver disease in children

被引:0
|
作者
Amiri, Fateme [1 ]
Moludi, Jalal [1 ]
Jouybari, Touraj Ahmadi [2 ]
Qasemi, Mahmoud [3 ]
Sharifi, Maryam [1 ]
Mahaki, Behzad [4 ]
Soleimani, Davood [1 ]
机构
[1] Kermanshah Univ Med Sci, Sch Nutr Sci & Food Technol, Dept Nutr Sci, Kermanshah, Iran
[2] Kermanshah Univ Med Sci, Imam Khomeini & Mohammad Kermanshahi & Farabi Hosp, Clin Res Dev Ctr, Kermanshah, Iran
[3] Kermanshah Univ Med Sci, Sch Med, Dept Pediat, Kermanshah, Iran
[4] Kermanshah Univ Med Sci, Sch Hlth, Dept Biostat, Kermanshah, Iran
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Non-alcoholic fatty liver disease; Fibrosis; Diet; Inflammation; Pediatrics; NONALCOHOLIC FATTY LIVER; METAANALYSIS; NUTRIENTS; PATTERN; RISK;
D O I
10.1038/s41598-025-89690-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Emerging research suggests a connection between dietary habits and metabolic dysfunction associated steatotic liver disease (MASLD). We aimed to assess the relationship between the Dietary Inflammatory Index (DII) and the severity of MASLD. This cross-sectional study involved 125 participants aged 7-18 with MASLD. Dietary intakes were assessed using a validated 147-item food frequency questionnaire. The DII was applied to measure diet-induced inflammation, categorizing diets into anti-inflammatory (DII < -1) and inflammatory diets (DII > + 1). To evaluate hepatic steatosis and fibrosis, transabdominal ultrasonography and the fibrosis-4 (FIB-4) index were utilized. After adjusting for potential confounding factors, individuals on inflammatory diets exhibited a significantly higher odds ratio (OR) for experiencing more severe steatosis (OR: 4.11; 95% CI: 1.08-15.71) compared to those on anti-inflammatory diets. Furthermore, each unit increase in DII scores was linked to a 2.6-fold increase in the odds of more severe steatosis (OR: 2.61; 95% CI: 1.28-5.32) and a 0.006 increase in FIB-4 scores (beta: 0.006; 95% CI: 0.003-0.011). In conclusion, modifying dietary intakes to lower DII scores may be a beneficial approach to improving clinical outcomes in pediatric MASLD, as anti-inflammatory diets are associated with reduced severity of hepatic steatosis and fibrosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86
  • [32] Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges
    Bader, Husam
    Yamin, Saif
    Alshahwan, Hamzeh
    Farraj, Husam
    Maghnam, Joud
    Omar, Yazan Abu
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [33] Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment
    Luo, Ling
    Ye, Junzhao
    Zhuo, Shuyu
    Ma, Bo
    Mai, Weiyi
    Cao, Xiaopei
    Liang, Liuqin
    Wang, Wei
    Feng, Shiting
    Dong, Zhi
    Zhong, Bihui
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (04)
  • [34] Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rubino, Jessica M.
    Ring, Natalie Yanzi
    Patel, Krishna
    Xia, Xiaoqing
    Mackenzie, Todd A.
    diFlorio-Alexander, Roberta M.
    BIOMEDICINES, 2025, 13 (01)
  • [35] Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease
    Behari, Jaideep
    Wang, Renwei
    Luu, Hung N.
    Mckenzie, David
    Molinari, Michele
    Yuan, Jian-Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (07)
  • [36] Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Llamoza-Torres, Camilo Julio
    Fuentes-Pardo, Maria
    Ramos-Molina, Bruno
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [37] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [38] Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)
    Canivet, C. M.
    Faure, S.
    REVUE DE MEDECINE INTERNE, 2024, 45 (01): : 41 - 47
  • [39] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [40] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10